Hi friends! Shane here! I just wanted to quick put up some reflections on my day today. I got my 7th Spinraza injection and ...

The author highlights the real-life impacts on the residents of Knoxville and East Tennessee from Trump administration cuts ...

It was Shane’s 8th Spinraza injection, a treatment that stops the progressive muscle-wasting associated with his disease.

There was no treatment until Doctor Adrian Krainer with Cold Spring Harbor lab on Long Island led the way to creation of Spinraza, a first FDA-approved treatment for Spinal Muscular Atrophy.

However while Spinraza had a very strong launch in the first half of 2017, its US sales faltered in Q3 to $197.6 million, barely above the $194.8 million achieve in the previous quarter.

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

The two other SMA stalwarts on the market, Biogen’s oligonucleotide Spinraza and Novartis’ gene therapy Zolgensma, are delivered intrathecally (into the cerebrospinal fluid around the spinal ...

The company's revenue hinges on products like Spinraza, as well as new launches such as Wainua, which has achieved promising early market penetration, and Tryngolza (olezarsen). During Q4 ...

The company, however, beat profit expectations for the fourth quarter, benefiting from a better-than-expected demand for its spinal muscular atrophy drug, Spinraza. Excluding certain items ...

The firm expanded its neurology portfolio beyond MS, including the blockbuster Spinraza for spinal muscular atrophy, or SMA, a rare neuromuscular disease. We see Biogen as a firm in transition ...

Ionis is a leader in RNA-based therapies, and its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The firm's ...